Addison, Texas, June 20, 2024 (GLOBE NEWSWIRE) -- MDB Capital Holdings, LLC, (NASDAQ:MDBH) ("MDB Capital"), a public venture platform focused on launching category-leading deep technology companies, today announced the appointment of Daniel Torpey to its Board of Directors, effective June 17, 2024. With the addition of Torpey, the MDB Capital Board now comprises eight members. Torpey brings over 24 years of experience at Ernst & Young LLP (EY), where he currently serves as an Assurance Partner in the Forensic & Integrity Services practice. His expertise spans accounting, auditing, compliance, financial reporting, fraud detection, and corporate investigations. "Dan's breadth of kn
Addison, TX, Nov. 02, 2023 (GLOBE NEWSWIRE) -- MDB Capital Holdings, LLC, (NASDAQ:MDBH) ("MDB"), a public venture platform with the objective of growing the public venture marketplace and optimizing the way meaningful technologies are financed and built, will hold a conference call on Wednesday, November 15, 2023, at 4:30 p.m. Eastern Time to discuss its results for the third quarter ended September 30, 2023. A press release detailing these results will be issued prior to the call. Christopher Marlett, CEO and Co-Founder of MDB will lead the call and will be joined by other members of the management team to review recent developments, ongoing initiatives, anticipated 2024 milestone
Record date of July 22, 2024 set for allocation preferences Closing and trading expected on NASDAQ on or before August 15 Addison, Texas, July 11, 2024 (GLOBE NEWSWIRE) -- MDB Capital Holdings, LLC, (NASDAQ:MDBH) ("MDB"), a public venture platform focused on launching category-leading deep technology companies, today announces the record date, allocation preference, and expected timeline for the proposed offering for Invizyne Technologies, Inc. In February 2024, Invizyne – a leading designer of cell-free, enzyme-based biomanufacturing systems to produce commercially important molecules and chemicals for everyday life and a subsidiary of MDB Capital Holdings – file
Transformative Innovations in MASH Diagnostics Dallas, Texas, July 09, 2024 (GLOBE NEWSWIRE) -- PatentVest, the first integrated IP intelligence strategy and law firm, recently published a whitepaper that presents strategic insights in the fields of Metabolic-Associated Steatohepatitis (MASH) biomarkers and Point of Care (PoC) kits for MASH diagnostics. This whitepaper serves as a valuable resource for stakeholders looking to navigate the complex and rapidly evolving landscape of these fields, offering guidance on capitalizing on innovation, collaboration, and IP protection to gain a competitive edge. "This rapid growing field is mainly driven by the recent Rezdiffra
ADDISON, Texas, July 08, 2024 (GLOBE NEWSWIRE) -- MDB Capital Holdings, LLC, (NASDAQ:MDBH) ("MDB"), a public venture platform focused on launching category-leading deep technology companies, today announced a collaboration through a patent and know-how agreement with Mayo Clinic to develop a small molecule anti-senescence platform. This collaboration aims to advance research in longevity and age-related disease prevention. Senescent cells, which are dysfunctional cells that have permanently stopped dividing, have been implicated in the aging process and the development of chronic low-grade inflammation. This chronic inflammation has been linked to a variety of age-related diseases, includ
Addison, Texas, June 20, 2024 (GLOBE NEWSWIRE) -- MDB Capital Holdings, LLC, (NASDAQ:MDBH) ("MDB Capital"), a public venture platform focused on launching category-leading deep technology companies, today announced the appointment of Daniel Torpey to its Board of Directors, effective June 17, 2024. With the addition of Torpey, the MDB Capital Board now comprises eight members. Torpey brings over 24 years of experience at Ernst & Young LLP (EY), where he currently serves as an Assurance Partner in the Forensic & Integrity Services practice. His expertise spans accounting, auditing, compliance, financial reporting, fraud detection, and corporate investigations. "Dan's breadth of kn
56% increase in global patent publications over the last five years signals growing interest in the cardiac monitoring market which is expected to grow to $3 billion per year by 2029 according to Statista.PatentVest's report provides groundbreaking insights into the evolving landscape of cardiac care, highlighting key players, technological advancements and the race for innovation. Dallas, TX, May 22, 2024 (GLOBE NEWSWIRE) -- Today, PatentVest, a leading provider of IP Strategy and IP Law services, announces the release of its latest report, "Pulse of Innovation: Shaping the Future of Cardiac Health Through Technology." This comprehensive study offers a deep dive into the rapidly ev
Addison, TX, May 22, 2024 (GLOBE NEWSWIRE) -- MDB Capital Holdings, LLC, (NASDAQ:MDBH) ("MDB"), a public venture platform focused on launching category-leading deep technology companies, today announces its self-clearing broker dealer and associated online and mobile trading platforms will now unify under one brand name, MDB Capital. "In response to feedback from our community, we decided to create continuity across our services to eliminate confusion. We believe the change makes it easier for prospective and current investors to navigate all our offerings by placing everything under a common ‘MDB Capital' platform," said Christopher Marlett, CEO and Co-Founder of MDB. Learn mor
Michael Heltzen appointed as CEO bringing 20 years of global commercial leadership experience and a track record of successful launches and exitsAdditional industry veterans join in key roles including business development, finance, and communications MONROVIA, Calif., May 07, 2024 (GLOBE NEWSWIRE) -- Invizyne Technologies, Inc., a leading designer of cell-free, enzyme-based biomanufacturing systems to produce commercially important molecules and chemicals for everyday life, today announced the appointment of Michael Heltzen as CEO, and the recent hirings of additional seasoned industry executives for its leadership team. "Michael Heltzen is a highly experienced technology entrepreneur
Addison, Texas, April 17, 2024 (GLOBE NEWSWIRE) -- MDB Capital Holdings, LLC, (NASDAQ:MDBH) ("MDB"), a public venture platform focused on launching category-leading deep technology companies, reported results for its fourth quarter and full year ended December 31, 2023, on form 10-K filed with the Securities and Exchange Commission, and will highlight recent corporate progress on today's call with management. "On the heels of completing our IPO on the NASDAQ in the third quarter of 2023, we've been working diligently to advance our self-clearing broker dealer capabilities to support our investor community, increasing the number of deep technology ideas we review and ultimately finan
Addison, Texas, April 11, 2024 (GLOBE NEWSWIRE) -- MDB Capital Holdings, LLC, (NASDAQ:MDBH) ("MDB"), a public venture platform with the objective of growing the public venture marketplace and optimizing the way meaningful technologies are financed and built, plans to host a Zoom webinar on Wednesday April 17, 2024 at 4:30 p.m. Eastern Time to discuss its results for the fourth quarter and full fiscal year ended December 31, 2023. A press release detailing these results will be issued prior to the call. Christopher Marlett, CEO and Co-Founder of MDB will lead the webinar and will be joined by other members of the management team to review recent developments, ongoing initiatives, anticipa
Cybin Inc. (NYSE:CYBN) (Cboe CA:CYBN) ("Cybin" or the "Company"), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative next-generation psychedelic-based treatment options, today announced participation in the upcoming Public Ventures Discovery Day on March 19, 2024 in Dallas, TX. Doug Drysdale, Chief Executive Officer of Cybin will participate in a fireside chat at the event and will be available to meet attendees during breakout sessions. Public Ventures Discovery Day Date: Tuesday, March 19, 2024 Presentation: 3:05 PM CT Location: Pecan Room, Old Parkland, 3819 Maple
Record date of July 22, 2024 set for allocation preferencesClosing and trading expected on NASDAQ on or before August 15Addison, Texas, July 11, 2024 (GLOBE NEWSWIRE) -- MDB Capital Holdings, LLC, (NASDAQ:MDBH) ("MDB"), a public venture platform focused on launching category-leading deep technology companies, today announces the record date, allocation preference, and expected timeline for the proposed offering for Invizyne Technologies, Inc.In February 2024, Invizyne – a leading designer of cell-free, enzyme-based biomanufacturing systems to produce commercially important molecules and chemicals for everyday life and a subsidiary of MDB Capital Holdings – filed its IPO registration stateme
Companies Reporting Before The Bell • Codere Online Luxembourg (NASDAQ:CDRO) is likely to report earnings for its third quarter. • Movano (NASDAQ:MOVE) is projected to report earnings for its third quarter. • Sypris Solutions (NASDAQ:SYPR) is estimated to report earnings for its third quarter. • LM Funding America (NASDAQ:LMFA) is projected to report earnings for its third quarter. • Milestone Scientific (AMEX:MLSS) is estimated to report earnings for its third quarter. • WiSA Technologies (NASDAQ:WISA) is estimated to report quarterly loss at $0.84 per share on revenue of $550 thousand. • AIM ImmunoTech (AMEX:AIM) is estimated to report quarterly loss at $0.11 per share on revenue of
Invizyne Technologies, Inc., a leading designer of enzyme-based biomanufacturing systems – and a "Big Idea" company from MDB Capital Holdings, LLC, (NASDAQ:MDBH) ("MDB") – today announced it received an additional $3.77 million grant from the Bioenergy Technologies Office (BETO) within the U.S. Department of Energy's (DOE's) Office of Energy Efficiency and Renewable Energy (EERE)."With our patented SimplePath™ technology platform, we developed a new way to make valuable chemicals from plant-based energy sources, thereby reducing the pollution associated with traditional production methods. This includes isobutanol, which is an industrial chemical with potential to significantly reduce green
Gainers TransCode Therapeutics, Inc. (NASDAQ:RNAZ) shares jumped 308% to $2.71 after the company announced pre-clinical gliblastoma results with its lead candidate, TTX-MC138. FaZe Holdings Inc. (NASDAQ:FAZE) gained 46.9% to $0.2247 after falling over 4% on Friday. Avalo Therapeutics, Inc. (NASDAQ:AVTX) shares climbed 23.5% to $0.1472 after gaining 16% on Friday. The company recently announced the sale of its assets relating to AVTX-801 (D-galactose), AVTX-802 (D-mannose) and AVTX-803 (L-fucose) on Sept. 12. Biophytis S.A. (NASDAQ:BPTS) shares gained 22.3% to $1.1250 after the company and Skyepharma announced the signature of a partnership agreement for the production of regulatory ba
Gainers MicroAlgo Inc. (NASDAQ:MLGO) shares jumped 74% to $7.02 after it unveiled a knowledge-enhanced backtracking search algorithm to boost the performance and efficiency of research institutions. Synaptogenix, Inc. (NASDAQ:SNPX) surged 28.7% to $0.3610. Lifezone Metals Limited (NYSE:LZM) gained 27.4% to $15.29. Lifezone Metals recently reported H1 loss of $16.77 per share. SeqLL Inc. (NASDAQ:SQL) gained 26% to $18.04. Heart Test Laboratories, Inc. (NASDAQ:HSCS) climbed 25.2% to $0.4680. Cemtrex, Inc. (NASDAQ:CETX) rose 21.7% to $6.86. Cheche Group Inc. (NASDAQ:CCG) gained 21.1% to $17.99 amid continued volatility following the company's business combination with Prime Impact Acqu
Gainers GSE Systems, Inc. (NASDAQ:GVP) shares rose 32.4% to $0.4090 in pre-market trading after falling over 3% on Thursday. Roadzen (NASDAQ:RDZN) shares rose 23.4% to $8.11 in pre-market trading after falling more than 40% on Thursday. FLJ Group Limited (NASDAQ:FLJ) shares gained 20.3% to $0.3669 in pre-market trading. Blue Star Foods Corp. (NASDAQ:BSFC) shares rose 17.1% to $0.37 in pre-market trading. Blue Star Foods recently announced closing of $5 million public offering. Avalo Therapeutics, Inc. (NASDAQ:AVTX) shares jumped 17% to $0.1199 in pre-market trading after falling 8% on Thursday. The company recently agreed to divest AVTX-800 series. Blue Water Biotech, Inc. (NASDAQ:BW
10-Q - MDB Capital Holdings, LLC (0001934642) (Filer)
8-K - MDB Capital Holdings, LLC (0001934642) (Filer)
8-K - MDB Capital Holdings, LLC (0001934642) (Filer)
S-8 - MDB Capital Holdings, LLC (0001934642) (Filer)
10-Q - MDB Capital Holdings, LLC (0001934642) (Filer)
10-K - MDB Capital Holdings, LLC (0001934642) (Filer)